Skip to main content
SpringerLink
Log in

Glycopeptides and Antibiotics for Gram-positive Bacterial Infections

  • Chapter
  • First Online:
Drug Dosing in Obesity

  • 833 Accesses

Abstract

Glycopeptides, lipopeptides and other antibiotics, such as linezolid and quinupristin/dalfopristin , are exclusively used for the treatment of infections caused by Gram-positive bacteria. Limited information is available about the dosing of these antibiotics in obese patients. This chapter aims to summarise the available evidence on the dosing of glycopeptides , lipopeptides , linezolid and quinupristin/dalfopristin in obesity. Specific dosing recommendations are also provided to aid clinical decisions making with regards to dosing of these antibiotics in obese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev. 2005;105(2):425–48.

    Article  CAS  PubMed  Google Scholar 

  2. Henson KE, Levine MT, Wong EA, Levine DP. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. Expert Rev Anti-infect Ther. 2015;12:1–14.

    Google Scholar 

  3. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother (Research Support, Non-U.S. Gov’t). 2011;45(6):757–63.

    Google Scholar 

  4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis: Off Publ Infect Dis Soc Am (Practice Guideline Research Support, Non-U.S. Gov’t). 2011;52(3):285–92.

    Google Scholar 

  5. Smith WJ, Drew RH. Telavancin: a new lipoglycopeptide for gram-positive infections. Drugs Today (Barc) (Review). 2009;45(3):159–73.

    Google Scholar 

  6. Arhin FF, Draghi DC, Pillar CM, Parr TR Jr, Moeck G, Sahm DF. Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates. Antimicrob Agents Chemother. 2009;53(11):4762–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet (Clinical Trial Comparative Study). 2004;43(13):925–42.

    Google Scholar 

  8. Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, et al. Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2013;57(4):1654–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis: Off Publ Infect Dis Soc Am. 2014;59(5):666–75.

    Article  CAS  Google Scholar 

  10. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can’t get there from here. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;52(8):969–74.

    Article  CAS  Google Scholar 

  11. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis: Off Publ Infect Dis Soc Am (Practice Guideline Research Support, Non-U.S. Gov’t). 2009;49(3):325–7.

    Google Scholar 

  12. Kuti JL, Kiffer CR, Mendes CM, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis. 2008;14(2):116–23.

    Article  CAS  Google Scholar 

  13. Hagihara M, Umemura T, Kimura M, Mori T, Hasegawa T, Mikamo H. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother: Off J Jpn Soc Chemother. 2012;18(1):10–6.

    Article  CAS  Google Scholar 

  14. Campana EH, Carvalhaes CG, Nonato B, Machado AM, Gales AC. Comparison of M.I.C.E. and Etest with CLSI agar dilution for antimicrobial susceptibility testing against oxacillin-resistant Staphylococcus spp. PLoS ONE. 2014;9(4):e94627.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70(7):859–86.

    Article  CAS  PubMed  Google Scholar 

  16. Wu G, Truong J, Lee S, Elnadoury O, Kuan W, Abraham T, et al. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections. Expert Rev Anti-infect Ther. 2015;13(4):409–16.

    CAS  PubMed  Google Scholar 

  17. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrobial Chemother (Review). 2012;67(6):1305–10.

    Google Scholar 

  18. Lamont E, Seaton RA, Macpherson M, Semple L, Bell E, Thomson AH. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. J Antimicrobial Chemother (Practice Guideline Research Support, Non-U.S. Gov’t). 2009;64(1):181–7.

    Google Scholar 

  19. Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015;59(6):3365–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrobial agents and chemotherapy. [Clinical Trial, Phase I Clinical Trial, Phase II Clinical Trial, Phase III Research Support, Non-U.S. Gov’t]. 2009 Oct;53(10):4422–8.

    Google Scholar 

  21. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacology (Clinical Trial, Phase II Clinical Trial, Phase III Multicenter Study). 2005;45(11):1279–87.

    Google Scholar 

  22. Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrobial Agents Chemother. [Research Support, Non-U.S. Gov’t]. 2012;56(4):2062–6.

    Google Scholar 

  23. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54(8):621–5.

    Article  CAS  PubMed  Google Scholar 

  24. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health-Syst Pharm: AJHP: Off J Am Soc Health-Syst Pharma (Comparative Study). 2009;66(7):642–8.

    Google Scholar 

  26. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993;37(3):436–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Reynolds DC, Waite LH, Alexander DP, Deryke CA. Performance of a vancomycin dosage regimen developed for obese patients. Am J Health-Syst Pharm: AJHP: Off J Am Soc Health-Syst Pharma. 2012;69(11):944–50.

    Article  CAS  Google Scholar 

  28. Kosmisky DEG, Griffiths CL, Templin MA, Norton J, Martin KE. Evaluation of a new vancomycin dosing protocol in morbidly obese patients. Hosp Pharm. 2015;50(9):789–97.

    Article  CAS  PubMed  Google Scholar 

  29. Hong J, Krop LC, Johns T, Pai MP. Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. Pharmacotherapy. 2015;35(5):455–63.

    Article  CAS  PubMed  Google Scholar 

  30. Brink AJ, Richards GA, Cummins RR, Lambson J. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis. Intl J Antimicrobial Agents (Clinical Trial Multicenter Study Research Support, Non-U.S. Gov’t). 2008;32(5):455–8.

    Google Scholar 

  31. Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet (Clinical Trial Comparative Study). 2004;43(6):405–15.

    Google Scholar 

  32. Mimoz O, Rolland D, Adoun M, Marchand S, Breilh D, Brumpt I, et al. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. Intensive Care Med (Research Support, Non-U.S. Gov’t). 2006;32(5):775–9.

    Google Scholar 

  33. Bhavnani SM, Passarell JA, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia. Antimicrobial Agents Chemother. (Comparative Study Research Support, Non-U.S. Gov’t). 2006;50(3):994–1000.

    Google Scholar 

  34. Samara E, Shaw JP, Barriere SL, Wong SL, Worboys P. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrobial Agents Chemother (Clinical Trial, Phase I Clinical Trial, Phase II Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov’t). 2012;56(4):2067–73.

    Google Scholar 

  35. Slover CM, NA, Barriere S, Lu Q. Telavancin (TLV) for treatment of complicated skin and skin structure infections (cSSSI) in obese patients. In: 51th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy September 17–20, 2011; Chicago, IL2011.

    Google Scholar 

  36. Vance-Bryan K, Larson TA, Rotschafer JC, Toscano JP. Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrobial agents and chemotherapy. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.]. 1992 Oct;36(10):2334–7.

    Google Scholar 

  37. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J. Clin Pharmacol (Clinical Trial Comparative Study Research Support, Non-U.S. Gov’t). 2005;45(1):48–56.

    Google Scholar 

  38. Pai MP, Norenberg JP, Anderson T, Goade DW, Rodvold KA, Telepak RA, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrobial Agents Chemother. (Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t). 2007;51(8):2741–7.

    Google Scholar 

  39. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155–64.

    Article  PubMed  Google Scholar 

  40. Bookstaver PB, Bland CM, Qureshi ZP, Faulkner-Fennell CM, Sheldon MA, Caulder CR, et al. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy (Multicenter Study). 2013;33(12):1322–30.

    Google Scholar 

  41. Gyssens I. Daptomycin. In: Grayson MLC, McCarthy J, Mills J, Mouton J, Norrby R, Paterson D, Pfaller M, editors. Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 6th ed. CRC Press; 2010. p. 621–37.

    Google Scholar 

  42. Ng JK, Schulz LT, Rose WE, Fox BC, Andes DR, Buhr KA, et al. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrobial Agents Chemother (Research Support, N.I.H., Extramural). 2014;58(1):88–93.

    Google Scholar 

  43. Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther. 2014;39(6):584–608.

    Article  CAS  PubMed  Google Scholar 

  44. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrobial Chemother. 2003;51 Suppl 2:ii17–25.

    Google Scholar 

  45. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 2003;42(15):1411–23.

    Article  CAS  PubMed  Google Scholar 

  46. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrobial Chemother. 2012;67(8):2034–42.

    Article  CAS  Google Scholar 

  47. Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother (Clinical Trial Research Support, Non-U.S. Gov’t). 2005;39(3):427–32.

    Google Scholar 

  48. De Pascale G, Fortuna S, Tumbarello M, Cutuli SL, Vallecoccia M, Spanu T, et al. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med. (Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t). 2015;41(1):103–10.

    Google Scholar 

  49. Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health-Syst Pharm: AJHP: Off J Am Soc Health-Syst Pharm (Case Reports Letter). 2005;62(5):464, 7.

    Google Scholar 

  50. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sadoh S, Kobayashi T, et al. Evaluation of the pharmacokinetics of linezolid in an obese Japanese patient. Scandinavian J Infect Dis. 2012;44:626–9.

    Google Scholar 

  51. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2003;36(4):473–81.

    Article  Google Scholar 

  52. Aeschlimann JR, Rybak MJ. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother. 1998;42(9):2188–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrobial Chemother. 1999;44 Suppl A:37–46.

    Google Scholar 

  54. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy (Review). 2007;27(8):1081–91.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy, School of Medicine, University of Tasmania, Private Bag 26, Hobart, TAS, 7001, Australia

    Syed Tabish R. Zaidi

  2. Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia

    Brett Janson

Authors
  1. Syed Tabish R. Zaidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brett Janson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed Tabish R. Zaidi .

Editor information

Editors and Affiliations

  1. Division of Pharmacy, School of Medicine, University of Tasmania School of Medicine, Hobart, Tasmania, Australia

    Syed Tabish R. Zaidi

  2. School of Medicine and School of Pharmacy, Burns, Trauma and Critical Care Res Cntr, University of Queensland Burns, Trauma and Critical Care Res Cntr, Brisbane, Queensland, Australia

    Jason A. Roberts

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zaidi, S.T.R., Janson, B. (2016). Glycopeptides and Antibiotics for Gram-positive Bacterial Infections. In: Zaidi, S., Roberts, J. (eds) Drug Dosing in Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-44034-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-44034-7_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-44032-3

  • Online ISBN: 978-3-319-44034-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation